Direkt zum Inhalt
  1. Publizieren |
  2. Suche |
  3. Browsen |
  4. Neuzugänge rss |
  5. Open Access |
  6. Rechtsfragen |
  7. EnglishCookie löschen - von nun an wird die Spracheinstellung Ihres Browsers verwendet.

Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma

Salwender, Hans ; Bertsch, Uta ; Weisel, Katja ; Duerig, Jan ; Kunz, Christina ; Benner, Axel ; Blau, Igor W. ; Raab, Marc Steffen ; Hillengass, Jens ; Hose, Dirk ; Huhn, Stefanie ; Hundemer, Michael ; Andrulis, Mindaugas ; Jauch, Anna ; Seidel-Glaetzer, Andrea ; Lindemann, Hans-Walter ; Hensel, Manfred ; Fronhoffs, Stefan ; Martens, Uwe ; Hansen, Timon ; Wattad, Mohammed ; Graeven, Ullrich ; Munder, Markus ; Fenk, Roland ; Haenel, Mathias ; Scheid, Christof ; Goldschmidt, Hartmut

In: BMC Cancer, 19 (2019), Nr. 504. S. 1-11. ISSN 1471-2407

[thumbnail of 12885_2019_Article_5600.pdf] PDF, Englisch - Hauptdokument
Download (830kB) | Lizenz: Creative Commons LizenzvertragRationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma von Salwender, Hans ; Bertsch, Uta ; Weisel, Katja ; Duerig, Jan ; Kunz, Christina ; Benner, Axel ; Blau, Igor W. ; Raab, Marc Steffen ; Hillengass, Jens ; Hose, Dirk ; Huhn, Stefanie ; Hundemer, Michael ; Andrulis, Mindaugas ; Jauch, Anna ; Seidel-Glaetzer, Andrea ; Lindemann, Hans-Walter ; Hensel, Manfred ; Fronhoffs, Stefan ; Martens, Uwe ; Hansen, Timon ; Wattad, Mohammed ; Graeven, Ullrich ; Munder, Markus ; Fenk, Roland ; Haenel, Mathias ; Scheid, Christof ; Goldschmidt, Hartmut steht unter einer Creative Commons Namensnennung 4.0

Zitieren von Dokumenten: Bitte verwenden Sie für Zitate nicht die URL in der Adresszeile Ihres Webbrowsers, sondern entweder die angegebene DOI, URN oder die persistente URL, deren langfristige Verfügbarkeit wir garantieren. [mehr ...]

Abstract

Background: Despite major advances in therapy, multiple myeloma is still an incurable malignancy in the majority of patients. To increase survival, deeper remissions (i.e. CR) translating into longer PFS need to be achieved. Incorporation of new drugs (i.e. bortezomib and lenalidomide) as induction and maintenance treatment in an intensified treatment concept, including high dose melphalan (200 mg/m2), has resulted in increased CR rates, and is considered the standard of care for younger patients. Elotuzumab in combination with lenalidomide and dexamethasone has given better results as lenalidomide and dexamethasone alone in a phase III trial. The GMMG-HD6 trial will be the first phase III trial investigating the role of elotuzumab in combination with bortezomib, lenalidomide and dexamethasone (VRD) induction/consolidation and lenalidomide maintenance within a high dose concept.

Methods: GMMG-HD6 is a randomized, open, multicenter phase III trial. The planned recruitment number is 564 NDMM patients. All patients will receive 4 VRD cycles as induction and undergo peripheral blood stem cell mobilization and harvesting. Thereafter they will be treated with high dose melphalan therapy plus autologous stem cell transplantation followed by 2 cycles of VRD consolidation and lenalidomide maintenance. Patients in arm B1 + B2 will additionally receive elotuzumab in the induction phase, whereas patients in A2 + B2 will be treated with elotuzumab added to consolidation and maintenance. The primary endpoint of the trial is PFS. Secondary objectives and endpoints are OS, CR rates after induction therapy comparing the two arms VRD (A1 + A2) vs VRD + elotuzumab (B1 + B2), CR rates after consolidation treatment, best response to treatment during the study, time to progression (TTP), duration of response (DOR), toxicity and quality of life.

Results: Since this is the publication of a study protocol of an ongoing study, no results can be presented.

Discussion: This phase III trial is designed to evaluate whether the addition of elotuzumab to an intensified treatment concept with high dose melphalan chemotherapy plus autologous stem cell transplantation and induction, consolidation and maintenance treatment with bortezomib and lenalidomide is able to improve PFS compared to the same concept without elotuzumab.

Trial registration: NCT02495922 on June 24th, 2015.

Dokumententyp: Artikel
Titel der Zeitschrift: BMC Cancer
Band: 19
Nummer: 504
Verlag: BioMed Central ; Springer
Ort der Veröffentlichung: London ; Berlin, Heidelberg
Erstellungsdatum: 06 Aug. 2019 12:45
Erscheinungsjahr: 2019
ISSN: 1471-2407
Seitenbereich: S. 1-11
Institute/Einrichtungen: Zentrale und Sonstige Einrichtungen > Deutsches Krebsforschungszentrum
Medizinische Fakultät Heidelberg und Uniklinikum > Institut für Humangenetik
Medizinische Fakultät Heidelberg und Uniklinikum > Koordinierungszentrum für Klinische Studien
DDC-Sachgruppe: 610 Medizin
Freie Schlagwörter: Multiple myeloma, elotuzumab, autologous stem cell transplant, high-dose chemotherapy
Leitlinien | Häufige Fragen | Kontakt | Impressum |
OA-LogoDINI-Zertifikat 2013Logo der Open-Archives-Initiative